Blood Podcast

In this episode we will review a study identifying cyclin-dependent kinase 6 (or CDK6) as a therapeutic target of NUP98-driven acute myeloid leukemia (or AML), learn more about the largest clinical dataset on cold agglutinin disease, and examine the effects of COVID-19 on coagulation parameters as well as bleeding and thrombosis in hospitalized patients.

In this episode we’ll review the risk of bleeding after initiating treatment for acquired hemophilia A, examine the functional effect of antibodies leading to immune TTP and how this can be used as a biomarker, and finally, a blast from the past – we will discuss a study that explores the intriguing possibility that a core component driving globin gene expression became active long ago.

This week we’ll review data that suggests the pro-inflammatory environment associated with aging alters hematopoietic stem cell function by inducing IL27 receptor alpha expression, examine a study attempting to optimize antiplatelet therapy in essential thrombocythemia, and learn more about a study by investigators who have proposed that myelodysplastic syndrome patients with mutations in SF3B1 identify a new subtype of that disease.

This week we will explore the impact of calreticulin (or CALR) haploinsufficiency on hematopoietic stem cell activity in the context of myeloproliferative neoplasms, explore mechanisms of leukemogenesis related to the E2A-PBX1 fusion protein in childhood B-cell acute lymphoblastic leukemia, and learn about the connection between intestinal microbiota, their metabolite short chain fatty acids and chronic graft versus host disease after allogeneic stem cell transplantation.

Rachel Grace, a pediatric hematologist from Harvard, and Achille Yolascon, a genetics professor from Naples, dive into the latest advancements in hematology. They discuss breakthroughs in managing pyruvate kinase deficiency and emerging gene therapy trials. The conversation highlights the significance of international registries in improving patient care and the complexities of diagnosing congenital dyserythropoietic anemias. Their insights on inherited anemias and the role of accurate genetic testing pave the way for innovative treatments.

In this week’s episode we’ll examine the cause and clinical significance of dysplastic hematopoiesis at time of diagnosis in patients with multiple myeloma, review a multi‐omics analysis of patients that have undergone blastic transformation of chronic myeloid leukemia, and learn about HLA alleles that are either risk factors or protective for immune-mediated TTP in Japan.

In this week’s episode we’ll review a study focusing on the causes and impact of the inflammation of aging on hematopoietic stem cell function, learn about the potential influence of the endothelial cell protein C receptor in the pathogenesis of hemophilic arthropathy, and assess a novel function of GPS2 on erythropoiesis.

In this week’s episode we’ll review results of a trial of venetoclax plus low-dose cytarabine in untreated patients with acute myeloid leukemia who are ineligible for intensive chemotherapy, learn how HRI-regulated transcription factor ATF4 activates BCL11A transcription to silence fetal hemoglobin expression, and assess new data demonstrating that aromatase is a novel neosubstrate of cereblon responsible for thrombocytopenia caused by immunomodulatory drugs.

This week’s episode will discuss the impact of sickle cell disease on the bone marrow vascular niche, highlight more about the evolution of retrovirus-infected premalignant T-cell clones in adult T-cell leukemia/lymphoma, and assess the outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome.

In this week’s episode we will review a report on the use of hydroxyurea as an alternative to transfusion therapy for the prevention of recurrent strokes in patients with sickle cell anemia, learn more about why some erythroblasts continue to produce hemoglobin F in adults, and review a study that explores cancer outcomes in patients with short telomere syndromes.